Regeneron Culls Losses After High-Dose Eylea Sales Disappoint
Regeneron stock fell slightly Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea. The post Regeneron Culls Losses After High-Dose Eylea Sales Disappoint appeared first on Investor's Business Daily.
Regeneron stock fell slightly Monday after the drugmaker preannounced light sales of a high-dose version of eye drug Eylea.
The post Regeneron Culls Losses After High-Dose Eylea Sales Disappoint appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
